{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:11:07Z","timestamp":1777579867876,"version":"3.51.4"},"reference-count":249,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012669","name":"Natural Science Foundation Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.prp.2025.156326","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:07:25Z","timestamp":1765037245000},"page":"156326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Advancing glioblastoma immunotherapy: Molecular pathways and innovative therapeutic strategies"],"prefix":"10.1016","volume":"278","author":[{"given":"Min","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaogang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5023","key":"10.1016\/j.prp.2025.156326_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.1.5023.841","article-title":"Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications","volume":"1","author":"Burnet","year":"1957","journal-title":"Br. Med J."},{"key":"10.1016\/j.prp.2025.156326_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Prog. Exp. Tumor Res"},{"key":"10.1016\/j.prp.2025.156326_bib3","series-title":"Cellular and Humoral Aspects of the Hypersensitive States","author":"Billingham","year":"1959"},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.prp.2025.156326_bib6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"issue":"6382","key":"10.1016\/j.prp.2025.156326_bib7","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.prp.2025.156326_bib8","doi-asserted-by":"crossref","unstructured":"R. Medikonda, A review of glioblastoma immunotherapy 1 151 J. Neuro Oncol.2021, 5114153.","DOI":"10.1007\/s11060-020-03448-1"},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib9","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer stem cells in glioblastoma","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1593\/tlo.09100","article-title":"Modeling adult gliomas using RCAS\/t-va technology","volume":"2","author":"Hambardzumyan","year":"2009","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.prp.2025.156326_bib11","doi-asserted-by":"crossref","first-page":"15017","DOI":"10.1038\/nrdp.2015.17","article-title":"Glioma","volume":"1","author":"Weller","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"7","key":"10.1016\/j.prp.2025.156326_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156326_bib14","doi-asserted-by":"crossref","unstructured":"Q.T. Ostrom, CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012 4 17 4 Neuro Oncol.2015, iv1iv62.","DOI":"10.1093\/neuonc\/nov189"},{"issue":"5","key":"10.1016\/j.prp.2025.156326_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40336-022-00489-6","article-title":"Epidemiology, risk factors, and prognostic factors of gliomas","volume":"10","author":"Pellerino","year":"2022","journal-title":"Clin. Transl. Imaging"},{"key":"10.1016\/j.prp.2025.156326_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155939","article-title":"Recent developments in cuproptosis of glioblastoma","volume":"269","author":"Chen","year":"2025","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.prp.2025.156326_bib17","doi-asserted-by":"crossref","first-page":"2055417","DOI":"10.1080\/21645515.2022.2055417","article-title":"Immunotherapy of glioblastoma: recent advances and future prospects","volume":"18","author":"Yuan","year":"2022","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.prp.2025.156326_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.155022","article-title":"Non-coding RNAs (ncRNAs) and multidrug resistance in glioblastoma: therapeutic challenges and opportunities","volume":"253","author":"Subaiea","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.prp.2025.156326_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155590","article-title":"Detailed pathological role of non-coding RNAs (ncRNAs) in regulating drug resistance of glioblastoma, and update","volume":"263","author":"Leili","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"20","key":"10.1016\/j.prp.2025.156326_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015037","article-title":"Glioblastoma immunotherapy: a systematic review of the present strategies and prospects for advancements","volume":"24","author":"Agosti","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/nox144","article-title":"Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma","volume":"20","author":"Mandel","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.prp.2025.156326_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.944452","article-title":"Advances in immunotherapy for glioblastoma multiforme","volume":"13","author":"Mahmoud","year":"2022","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.prp.2025.156326_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202500131","article-title":"Genetically Engineered IL12\/CSF1R-macrophage membrane-liposome hybrid nanovesicles for NIR-II fluorescence imaging-guided and membrane-targeted mild photothermal-immunotherapy of glioblastoma","volume":"12","author":"Chen","year":"2025","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib25","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1186\/s12951-024-03074-3","article-title":"Bright NIR-II emissive cyanine dye-loaded lipoprotein-mimicking nanoparticles for fluorescence imaging-guided and targeted NIR-II photothermal therapy of subcutaneous glioblastoma","volume":"22","author":"Huang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.prp.2025.156326_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.114258","article-title":"Engineering of exosome-liposome hybrid-based theranostic nanomedicines for NIR-II fluorescence imaging-guided and targeted NIR-II photothermal therapy of subcutaneous glioblastoma","volume":"245","author":"Liu","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.prp.2025.156326_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114821","article-title":"Recent progress in NIR-II fluorescence imaging-guided drug delivery for cancer theranostics","volume":"197","author":"Roy","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.prp.2025.156326_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114539","article-title":"Ultrasound-mediated blood-brain barrier opening: an effective drug delivery system for theranostics of brain diseases","volume":"190","author":"Wang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2025.156326_bib32","doi-asserted-by":"crossref","first-page":"1255611","DOI":"10.3389\/fimmu.2023.1255611","article-title":"Immunotherapy: a promising approach for glioma treatment","volume":"14","author":"Yasinjan","year":"2023","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/brainsci7120166","article-title":"Advances in brain tumor surgery for glioblastoma in adults","volume":"7","author":"Lara-Velazquez","year":"2017","journal-title":"Brain Sci."},{"issue":"18","key":"10.1016\/j.prp.2025.156326_bib34","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1001\/jama.2012.14523","article-title":"The role of early resection vs biopsy in the management of low-grade gliomas","volume":"308","author":"Markert","year":"2012","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.prp.2025.156326_bib35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(11)70196-6","article-title":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial","volume":"12","author":"Senft","year":"2011","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11060-014-1597-9","article-title":"The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?","volume":"120","author":"Chaichana","year":"2014","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/neuonc\/not137","article-title":"Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma","volume":"16","author":"Chaichana","year":"2014","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J. Neurosurg."},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib39","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA A Cancer Journal Clinicians"},{"key":"10.1016\/j.prp.2025.156326_bib40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.wneu.2018.04.016","article-title":"The survival effect of repeat surgery at Glioblastoma recurrence and its trend: a systematic review and meta-analysis","volume":"115","author":"Lu","year":"2018","journal-title":"World Neurosurg."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib41","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00023210-200721090-00006","article-title":"Clinical impact of adjuvant chemotherapy in Glioblastoma Multiforme","volume":"21","author":"Spiegel","year":"2007","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5732\/cjc.013.10216","article-title":"Radiation and concomitant chemotherapy for patients with glioblastoma multiforme","volume":"33","author":"Vill\u00e0","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.prp.2025.156326_bib43","article-title":"Advances in radiotherapy for Glioblastoma","volume":"8 - 2017","author":"Mann","year":"2018","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for Glioblastoma: the promise of combination strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib48","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib49","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd.2018.210","article-title":"The clinical trial landscape for PD1\/PDL1 immune checkpoint inhibitors","volume":"17","author":"Tang","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall\u2019Olio","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.156326_bib51","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.wneu.2018.04.020","article-title":"Immunotherapy in Glioblastoma","volume":"116","author":"Wilcox","year":"2018","journal-title":"World Neurosurg."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib53","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma","volume":"25","author":"Zhao","year":"2019","journal-title":"Nat. Med"},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib54","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s43018-021-00260-2","article-title":"ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma","volume":"2","author":"Arrieta","year":"2021","journal-title":"Nat. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1501137","article-title":"Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models","volume":"7","author":"Genoud","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib56","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41467-024-48326-w","article-title":"Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas","volume":"15","author":"Arrieta","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib57","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpha.2023.04.012","article-title":"Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C","volume":"13","author":"Zhu","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.prp.2025.156326_bib58","article-title":"Immunosuppression in Gliomas via PD-1\/PD-L1 Axis and Adenosine Pathway","volume":"10","author":"Scheffel","year":"2020","journal-title":"Front. Oncol."},{"issue":"18","key":"10.1016\/j.prp.2025.156326_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202310163","article-title":"Metabolism\/immunity dual-regulation thermogels potentiating immunotherapy of glioblastoma through lactate-excretion inhibition and PD-1\/PD-L1 blockade","volume":"11","author":"Li","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.prp.2025.156326_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115790","article-title":"Intratumoral IL-12 delivery via mesenchymal stem cells combined with PD-1 blockade leads to long-term antitumor immunity in a mouse glioblastoma model","volume":"173","author":"Park","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib61","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1078-0432.CCR-23-1889","article-title":"ERK1\/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1\/CTLA-4 Immunotherapy: A REMARK-guided Analysis","volume":"30","author":"Arrieta","year":"2024","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib62","first-page":"vdac076","article-title":"Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma","volume":"4","author":"Daniel","year":"2022","journal-title":"Neurooncol Adv."},{"issue":"5","key":"10.1016\/j.prp.2025.156326_bib63","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.21873\/invivo.13296","article-title":"Humanized PD-1 knock-in mice reveal nivolumab's inhibitory effects on glioblastoma tumor progression In Vivo","volume":"37","author":"Chiang","year":"2023","journal-title":"Vivo"},{"issue":"11","key":"10.1016\/j.prp.2025.156326_bib64","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/neuonc\/noae135","article-title":"Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas","volume":"26","author":"Kim","year":"2024","journal-title":"Neuro Oncol."},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib65","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/neuonc\/noae177","article-title":"Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma","volume":"26","author":"Duerinck","year":"2024","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib66","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1525243","article-title":"Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma","volume":"8","author":"Park","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib67","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-023-04449-6","article-title":"Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy","volume":"165","author":"Hou","year":"2023","journal-title":"J. Neurooncol"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib68","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/2326-6066.CIR-22-0570","article-title":"Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression","volume":"11","author":"Tritz","year":"2023","journal-title":"Cancer Immunol. Res"},{"issue":"45","key":"10.1016\/j.prp.2025.156326_bib69","doi-asserted-by":"crossref","first-page":"eabh2148","DOI":"10.1126\/sciadv.abh2148","article-title":"PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NF\u03baB pathway","volume":"7","author":"Mirzaei","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib70","doi-asserted-by":"crossref","first-page":"18444","DOI":"10.1038\/s41598-024-67437-4","article-title":"Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth","volume":"14","author":"Yan","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2025.156326_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637146","article-title":"TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma","volume":"12","author":"Raphael","year":"2021","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib72","article-title":"Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib73","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1007\/s12035-024-04406-y","article-title":"Arming AAV9 with a single-chain fragment variable antibody against PD-1 for systemic Glioblastoma therapy","volume":"62","author":"Maksoud","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"17","key":"10.1016\/j.prp.2025.156326_bib74","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1158\/1078-0432.CCR-19-4110","article-title":"Anti-PD-1 Induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 Cytotoxic T cells","volume":"26","author":"Rao","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib75","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/1078-0432.CCR-19-1068","article-title":"4-1BB agonism averts TIL exhaustion and Licenses PD-1 blockade in Glioblastoma and other intracranial cancers","volume":"26","author":"Woroniecka","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"13","key":"10.1016\/j.prp.2025.156326_bib77","doi-asserted-by":"crossref","first-page":"11689","DOI":"10.1007\/s00432-023-05026-0","article-title":"Immune micro-environment analysis and establishment of response prediction model for PD-1 blockade immunotherapy in glioblastoma based on transcriptome deconvolution","volume":"149","author":"Wong","year":"2023","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib78","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00262-024-03770-x","article-title":"TRP-2 \/ gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors","volume":"73","author":"Pearson","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib79","doi-asserted-by":"crossref","first-page":"1956142","DOI":"10.1080\/2162402X.2021.1956142","article-title":"Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma","volume":"10","author":"Choi","year":"2021","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib80","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/1078-0432.CCR-18-1176","article-title":"Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation","volume":"25","author":"Davidson","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2025.156326_bib81","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52253","article-title":"Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy","volume":"9","author":"Cui","year":"2020","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib82","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/neuonc\/noab181","article-title":"ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma","volume":"24","author":"Huang","year":"2022","journal-title":"Neuro Oncol."},{"issue":"29","key":"10.1016\/j.prp.2025.156326_bib83","doi-asserted-by":"crossref","first-page":"20681","DOI":"10.18632\/oncotarget.25061","article-title":"Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma","volume":"9","author":"Garzon-Muvdi","year":"2018","journal-title":"Oncotarget"},{"issue":"370","key":"10.1016\/j.prp.2025.156326_bib84","doi-asserted-by":"crossref","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","article-title":"Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM","volume":"8","author":"Mathios","year":"2016","journal-title":"Sci. Transl. Med"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib86","doi-asserted-by":"crossref","DOI":"10.3892\/or.2024.8835","article-title":"Compression force promotes glioblastoma progression through the Piezo1\u2011GDF15\u2011CTLA4 axis","volume":"53","author":"Kim","year":"2025","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2025.156326_bib87","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.2147\/JIR.S341981","article-title":"CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment","volume":"14","author":"Guan","year":"2021","journal-title":"J. Inflamm. Res"},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib88","doi-asserted-by":"crossref","first-page":"5","DOI":"10.17691\/stm2023.15.3.01","article-title":"Fluorescence Lifetime Imaging of NAD(P)H T Cells Autofluorescence in the Lymphatic Nodes to Assess the Effectiveness of Anti-CTLA-4 Immunotherapy","volume":"15","author":"Izosimova","year":"2023","journal-title":"Sovrem. Tekhnologii Med"},{"key":"10.1016\/j.prp.2025.156326_bib89","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbi.2017.01.022","article-title":"Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4\/PD-L1 inhibition in mouse glioblastoma","volume":"62","author":"Zhai","year":"2017","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib90","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12865-024-00639-7","article-title":"Histone acetylation risk model predicts prognosis and guides therapy selection in glioblastoma: implications for chemotherapy and anti-CTLA-4 immunotherapy","volume":"25","author":"Jin","year":"2024","journal-title":"BMC Immunol."},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib91","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s00432-024-05997-8","article-title":"Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab","volume":"150","author":"Wang","year":"2024","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib92","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro Oncol."},{"issue":"14","key":"10.1016\/j.prp.2025.156326_bib93","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1158\/1078-0432.CCR-16-1369","article-title":"Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy","volume":"23","author":"Bloch","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib94","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1158\/1078-0432.CCR-21-4064","article-title":"Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma","volume":"28","author":"Nayak","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib95","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2767-9764.CRC-22-0420","article-title":"A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma","volume":"3","author":"Chiu","year":"2023","journal-title":"Cancer Res. Commun."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib96","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1038\/s41467-025-56930-7","article-title":"Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I\/II trial","volume":"16","author":"Weathers","year":"2025","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib97","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"npj Vaccin."},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib99","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","article-title":"Enhancing in situ cancer vaccines using delivery technologies","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-024-01091-9","article-title":"Vax-Innate: improving therapeutic cancer vaccines by modulating T cells and the tumour microenvironment","volume":"25","author":"Baharom","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib101","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","author":"van der Burg","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib103","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1150","article-title":"Cancer vaccines: between the idea and the reality","volume":"3","author":"Finn","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib104","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.156326_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.155983","article-title":"Vaccination and personalized cancer vaccines focusing on common cancers in women: A narrative review","volume":"270","author":"Ghahfarrokhi","year":"2025","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.prp.2025.156326_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14051025","article-title":"Combination of DNA vaccine and immune checkpoint blockades improves the immune response in an orthotopic unresectable Glioblastoma model","volume":"14","author":"Bausart","year":"2022","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib107","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1007\/s12035-024-03937-8","article-title":"HCMV IE1\/IE1mut therapeutic vaccine induces tumor regression via intratumoral tertiary lymphoid structure formation and peripheral immunity activation in Glioblastoma Multiforme","volume":"61","author":"Yang","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.prp.2025.156326_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.850546","article-title":"Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform","volume":"12","author":"Adhikari","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib109","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11060-019-03336-3","article-title":"Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy","volume":"146","author":"Alcaide-Leon","year":"2020","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41016-022-00301-4","article-title":"Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development","volume":"8","author":"Wang","year":"2022","journal-title":"Chin. Neurosurg. J."},{"key":"10.1016\/j.prp.2025.156326_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107265","article-title":"Immuno-informatics analysis and expression of a novel multi-domain antigen as a vaccine candidate against glioblastoma","volume":"91","author":"Gharbavi","year":"2021","journal-title":"Int Immunopharmacol."},{"issue":"7","key":"10.1016\/j.prp.2025.156326_bib112","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13864","article-title":"GM-CSF and IL-7 fusion cytokine engineered tumor vaccine generates long-term Th-17 memory cells and increases overall survival in aged syngeneic mouse models of glioblastoma","volume":"22","author":"Shireman","year":"2023","journal-title":"Aging Cell"},{"key":"10.1016\/j.prp.2025.156326_bib113","article-title":"Identification of tumor antigens and immune subtypes of glioblastoma for mRNA Vaccine Development","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib114","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40537-022-00643-x","article-title":"Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development","volume":"9","author":"Wu","year":"2022","journal-title":"J. Big Data"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNF.0000000000000452","article-title":"The Efficacy of dendritic cell vaccine for newly diagnosed Glioblastoma: a meta-analysis of randomized controlled studies","volume":"44","author":"Tan","year":"2021","journal-title":"Clin. Neuropharmacol."},{"issue":"677","key":"10.1016\/j.prp.2025.156326_bib116","doi-asserted-by":"crossref","first-page":"eabo4778","DOI":"10.1126\/scitranslmed.abo4778","article-title":"Bifunctional cancer cell-based vaccine concomitantly drives direct tumor killing and antitumor immunity","volume":"15","author":"Chen","year":"2023","journal-title":"Sci. Transl. Med"},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib117","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11060-024-04798-w","article-title":"Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis","volume":"170","author":"Wong","year":"2024","journal-title":"J. Neurooncol."},{"issue":"7738","key":"10.1016\/j.prp.2025.156326_bib118","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002426","article-title":"IFN-\u03b3- and IL-17-producing CD8(+) T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity","volume":"9","author":"Ohkuri","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40478-018-0621-2","article-title":"Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables","volume":"6","author":"Erhart","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"20","key":"10.1016\/j.prp.2025.156326_bib121","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-20-1082","article-title":"Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma","volume":"26","author":"Batich","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib122","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/cas.12055","article-title":"Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma","volume":"104","author":"Tanaka","year":"2013","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib123","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","article-title":"A Phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma","volume":"28","author":"Hu","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib124","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/1535-7163.MCT-09-0124","article-title":"An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme","volume":"8","author":"Sampson","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/2011.4.JNS10377","article-title":"Phase I\/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article","volume":"115","author":"Muragaki","year":"2011","journal-title":"J. Neurosurg."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib126","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2010.29.7499","article-title":"Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme","volume":"29","author":"Terasaki","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.prp.2025.156326_bib127","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-16-0506","article-title":"A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma","volume":"22","author":"Rampling","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3171\/2022.12.JNS221221","article-title":"A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas","volume":"139","author":"Muragaki","year":"2023","journal-title":"J. Neurosurg."},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib129","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1349-7006.2007.00518.x","article-title":"Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients","volume":"98","author":"Ishikawa","year":"2007","journal-title":"Cancer Sci."},{"issue":"19","key":"10.1016\/j.prp.2025.156326_bib130","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","article-title":"A randomized double-blind placebo-controlled phase II Trial of Dendritic Cell Vaccine ICT-107 in newly diagnosed patients with Glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"5-6","key":"10.1016\/j.prp.2025.156326_bib131","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.wneu.2011.08.020","article-title":"Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial","volume":"77","author":"Cho","year":"2012","journal-title":"World Neurosurg."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib132","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib134","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib136","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.prp.2025.156326_bib137","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/neuonc\/noy032","article-title":"CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges","volume":"20","author":"Bagley","year":"2018","journal-title":"Neuro Oncol."},{"issue":"14","key":"10.1016\/j.prp.2025.156326_bib138","doi-asserted-by":"crossref","first-page":"7090","DOI":"10.7150\/thno.114257","article-title":"Overcoming barriers in glioblastoma: The potential of CAR T cell immunotherapy","volume":"15","author":"Ijaz","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib139","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13046-023-02815-w","article-title":"Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation","volume":"42","author":"Sun","year":"2023","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib140","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005583","article-title":"Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice","volume":"11","author":"Dong","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib141","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib142","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1038\/s41596-020-0402-9","article-title":"Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing","volume":"15","author":"Jacob","year":"2020","journal-title":"Nat. Protoc."},{"issue":"656","key":"10.1016\/j.prp.2025.156326_bib143","doi-asserted-by":"crossref","first-page":"eabn1128","DOI":"10.1126\/scitranslmed.abn1128","article-title":"Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy","volume":"14","author":"Chen","year":"2022","journal-title":"Sci. Transl. Med"},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib144","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","article-title":"IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","volume":"26","author":"Hou","year":"2024","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib145","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","article-title":"CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy","volume":"14","author":"Chang","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib146","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib147","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib148","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.prp.2025.156326_bib149","article-title":"CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma","volume":"15 - 2021","author":"Maggs","year":"2021","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/ph14030236","article-title":"Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells","volume":"14","author":"Burster","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"7","key":"10.1016\/j.prp.2025.156326_bib151","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/cells10071641","article-title":"The Role of NKT Cells in Glioblastoma","volume":"10","author":"Brettschneider","year":"2021","journal-title":"Cells"},{"issue":"null","key":"10.1016\/j.prp.2025.156326_bib152","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/OTT.S486411","article-title":"Research Progress of NK Cells in Glioblastoma Treatment","volume":"18","author":"Wu","year":"2025","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.prp.2025.156326_bib153","article-title":"CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy","volume":"10 - 2019","author":"Burger","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib154","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-021-03787-7","article-title":"Glioblastoma cells potentiate the induction of the Th1-like profile in phosphoantigen-stimulated \u03b3\u03b4 T lymphocytes","volume":"153","author":"Rosso","year":"2021","journal-title":"J. Neuro Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-010-0245-2","article-title":"Preclinical evaluation of ex vivo expanded\/activated \u03b3\u03b4 T cells for immunotherapy of glioblastoma multiforme","volume":"101","author":"Bryant","year":"2011","journal-title":"J. Neuro Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051805","article-title":"Engineered Drug Resistant \u03b3\u03b4 T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy","volume":"8","author":"Lamb","year":"2013","journal-title":"PLOS ONE"},{"issue":"24","key":"10.1016\/j.prp.2025.156326_bib157","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3390\/cancers15245784","article-title":"The Role of \u03b3\u03b4 T-Lymphocytes in Glioblastoma: Current Trends and Future Directions","volume":"15","author":"Ahmedna","year":"2023","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.prp.2025.156326_bib158","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3390\/cancers17162660","article-title":"\u03b3\u03b4 T Cells in Glioblastoma Multiforme: Novel Roles and Therapeutic Opportunities","volume":"17","author":"Dieli","year":"2025","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib159","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/1078-0432.CCR-19-1068","article-title":"4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers","volume":"26","author":"Woroniecka","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib160","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1038\/bjc.2014.162","article-title":"Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma","volume":"110","author":"Han","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib161","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002620000142","article-title":"Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to Fc\u03b3RI and the epidermal growth factor receptor","volume":"49","author":"Wallace","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"issue":"16","key":"10.1016\/j.prp.2025.156326_bib162","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1073\/pnas.1525360113","article-title":"Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival","volume":"113","author":"Kloepper","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib163","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1073\/pnas.1219817110","article-title":"Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma","volume":"110","author":"Choi","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib164","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1535-7163.MCT-22-0201","article-title":"A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma","volume":"21","author":"Iurlaro","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib165","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163446","article-title":"Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy","volume":"133","author":"Khan","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.prp.2025.156326_bib166","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.canlet.2018.11.016","article-title":"Hybrids by tumor-associated macrophages \u00d7 glioblastoma cells entail nuclear reprogramming and glioblastoma invasion","volume":"442","author":"Cao","year":"2019","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.prp.2025.156326_bib167","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","article-title":"Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.prp.2025.156326_bib168","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2009290118","article-title":"PI3K\u03b3 inhibition suppresses microglia\/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response","volume":"118","author":"Li","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2025.156326_bib169","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2024.03.043","article-title":"M-MDSCs mediated trans-BBB drug delivery for suppression of glioblastoma recurrence post-standard treatment","volume":"369","author":"Yu","year":"2024","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib170","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/neuonc\/nor042","article-title":"Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma","volume":"13","author":"Raychaudhuri","year":"2011","journal-title":"Neuro Oncol."},{"issue":"null","key":"10.1016\/j.prp.2025.156326_bib171","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.2147\/CMAR.S210545","article-title":"LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression","volume":"11","author":"Chai","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"6731","key":"10.1016\/j.prp.2025.156326_bib172","doi-asserted-by":"crossref","first-page":"eabm5214","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma","volume":"387","author":"Jackson","year":"2025","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib173","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1038\/s41467-021-23832-3","article-title":"Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib174","first-page":"2592","article-title":"Identification of CD70-mediated Apoptosis of Immune Effector Cells as a Novel Immune Escape Pathway of Human Glioblastoma1","volume":"62","author":"Wischhusen","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/neuonc\/nox125","article-title":"Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF\u2013expressing tumor cells","volume":"20","author":"Jahan","year":"2017","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib176","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-015-0307-3","article-title":"OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy","volume":"14","author":"Shibahara","year":"2015","journal-title":"Mol. Cancer"},{"issue":"5-6","key":"10.1016\/j.prp.2025.156326_bib177","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18632\/oncoscience.505","article-title":"4-1BB Agonism as a strategy to license immune checkpoint blockade in glioblastoma","volume":"7","author":"Woroniecka","year":"2020","journal-title":"Oncoscience"},{"issue":"7","key":"10.1016\/j.prp.2025.156326_bib178","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101764","article-title":"Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model","volume":"9","author":"Belcaid","year":"2014","journal-title":"PLOS ONE"},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108353","article-title":"TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma","volume":"26","author":"Lupo","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.prp.2025.156326_bib180","article-title":"Immunotherapy for Glioblastoma: current progress and challenges","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib181","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5306\/wjco.v14.i4.138","article-title":"Immunotherapy in glioblastoma treatment: Current state and future prospects","volume":"14","author":"Rocha Pinheiro","year":"2023","journal-title":"World J. Clin. Oncol."},{"issue":"591","key":"10.1016\/j.prp.2025.156326_bib182","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"21","key":"10.1016\/j.prp.2025.156326_bib183","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","article-title":"Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma","volume":"28","author":"Meister","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2025.156326_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116436","article-title":"CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment","volume":"174","author":"Kong","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"399","key":"10.1016\/j.prp.2025.156326_bib185","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.prp.2025.156326_bib186","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib187","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib188","doi-asserted-by":"crossref","first-page":"2127508","DOI":"10.1080\/2162402X.2022.2127508","article-title":"AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma","volume":"11","author":"Strecker","year":"2022","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib189","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","article-title":"Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders","volume":"8","author":"Xia","year":"2024","journal-title":"Nat. Biomed. Eng."},{"issue":"533","key":"10.1016\/j.prp.2025.156326_bib190","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2672","article-title":"Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma","volume":"12","author":"Wang","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib191","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib192","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.cell.2021.03.023","article-title":"Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion","volume":"184","author":"Gangoso","year":"2021","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib193","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1038\/s41591-024-03138-9","article-title":"Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells","volume":"30","author":"Chokshi","year":"2024","journal-title":"Nat. Med"},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib194","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00262-024-03808-0","article-title":"Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model","volume":"73","author":"Tachi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib195","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib196","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1038\/s41467-022-32311-2","article-title":"Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands","volume":"13","author":"Zhong","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib197","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12935-024-03234-3","article-title":"IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion","volume":"24","author":"Zhao","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"17","key":"10.1016\/j.prp.2025.156326_bib198","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174257","article-title":"Vascular immune evasion of mesenchymal glioblastoma is mediated by interaction and regulation of VE-Cadherin on PD-L1","volume":"15","author":"Luo","year":"2023","journal-title":"Cancers"},{"issue":"27","key":"10.1016\/j.prp.2025.156326_bib199","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202206380","article-title":"EGFR-Induced and c-Src-Mediated CD47 phosphorylation inhibits TRIM21-dependent polyubiquitylation and degradation of CD47 to promote tumor immune evasion","volume":"10","author":"Du","year":"2023","journal-title":"Adv. Sci."},{"issue":"11","key":"10.1016\/j.prp.2025.156326_bib200","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191115","article-title":"\u03b2-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion","volume":"217","author":"Du","year":"2020","journal-title":"J. Exp. Med"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib201","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/s41467-022-29137-3","article-title":"Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib202","first-page":"vdae012","article-title":"Potential roles for efferocytosis in glioblastoma immune evasion","volume":"6","author":"Lorimer","year":"2024","journal-title":"Neurooncol Adv."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib203","doi-asserted-by":"crossref","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib204","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002181","article-title":"Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma","volume":"9","author":"Simonds","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib205","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s13258-022-01291-4","article-title":"Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion","volume":"44","author":"Wang","year":"2022","journal-title":"Genes Genom."},{"issue":"35","key":"10.1016\/j.prp.2025.156326_bib206","doi-asserted-by":"crossref","first-page":"12823","DOI":"10.1073\/pnas.1413933111","article-title":"Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients","volume":"111","author":"Crane","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib207","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41419-023-05878-x","article-title":"Epigenetically modified AP-2\u03b1 by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression","volume":"14","author":"Long","year":"2023","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib208","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/stem.2393","article-title":"Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion","volume":"34","author":"Otvos","year":"2016","journal-title":"Stem Cells"},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166155","article-title":"TLR4 expression and functionality are downregulated in glioblastoma cells and in tumor-associated macrophages: A new mechanism of immune evasion?","volume":"1867","author":"da Cruz","year":"2021","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib210","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1620\/tjem.2023.J028","article-title":"MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma","volume":"260","author":"Du","year":"2023","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.prp.2025.156326_bib211","article-title":"PTRF\/Cavin-1 as a Novel RNA-binding protein expedites the NF-\u03baB\/PD-L1 axis by stabilizing lncRNA NEAT1, contributing to tumorigenesis and immune evasion in Glioblastoma","volume":"12","author":"Yi","year":"2021","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib212","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1227\/01.NEU.0000255460.91892.44","article-title":"Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas","volume":"60","author":"Anderson","year":"2007","journal-title":"Neurosurgery"},{"issue":"7","key":"10.1016\/j.prp.2025.156326_bib213","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-18-0599","article-title":"Reduced neoantigen expression revealed by longitudinal multiomics as a possible immune evasion mechanism in glioma","volume":"7","author":"Nejo","year":"2019","journal-title":"Cancer Immunol. Res"},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib214","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/2326-6066.CIR-18-0020","article-title":"TLR2 promotes glioma immune evasion by downregulating MHC Class II molecules in microglia","volume":"6","author":"Qian","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"18","key":"10.1016\/j.prp.2025.156326_bib215","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/WNR.0b013e32833188f7","article-title":"Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion","volume":"20","author":"Han","year":"2009","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib216","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12935-024-03234-3","article-title":"IGFBP3 induces PD-L1 expression to promote glioblastoma immune evasion","volume":"24","author":"Zhao","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib217","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s42003-024-06488-9","article-title":"Integrative analysis of genomic and epigenomic regulation reveals miRNA mediated tumor heterogeneity and immune evasion in lower grade glioma","volume":"7","author":"Yang","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.prp.2025.156326_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114453","article-title":"The miR-192\/EGR1-HOXB9 loop inhibits immune evasion in glioma by arresting their NSC phenotypes","volume":"152","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"14","key":"10.1016\/j.prp.2025.156326_bib219","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2321611121","article-title":"NSUN5\/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion","volume":"121","author":"Wu","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"16","key":"10.1016\/j.prp.2025.156326_bib220","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib221","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-21-0947","article-title":"Long-acting recombinant human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and enhances survival in mouse glioma models","volume":"28","author":"Campian","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"13","key":"10.1016\/j.prp.2025.156326_bib222","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137046","article-title":"Immunotherapy in Glioblastoma: current approaches and future perspectives","volume":"23","author":"Sener","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib223","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/s42003-024-07144-y","article-title":"ZBTB18 regulates cytokine expression and affects microglia\/macrophage recruitment and commitment in glioblastoma","volume":"7","author":"Ferrarese","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.prp.2025.156326_bib224","article-title":"Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity","volume":"42","author":"Brem","year":"2024","journal-title":"Brain Behav. Immun. Health"},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib225","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s43018-023-00658-0","article-title":"Lymphatic endothelial-like cells promote glioblastoma stem cell growth through cytokine-driven cholesterol metabolism","volume":"5","author":"Zhao","year":"2024","journal-title":"Nat. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib226","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.21873\/anticanres.13315","article-title":"Immune phenotype correlates with survival in patients with GBM treated with standard temozolomide-based therapy and immunotherapy","volume":"39","author":"Antonopoulos","year":"2019","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.prp.2025.156326_bib227","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1172\/JCI138649","article-title":"Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib228","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.18632\/oncotarget.12273","article-title":"Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.prp.2025.156326_bib229","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3174\/ajnr.A7488","article-title":"Radiomics-based machine learning for outcome prediction in a multicenter Phase II Study of Programmed Death-Ligand 1 inhibition immunotherapy for Glioblastoma","volume":"43","author":"George","year":"2022","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01533386","article-title":"Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients","volume":"39","author":"Boiardi","year":"1994","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib231","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1078-0432.CCR-10-2563","article-title":"Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy","volume":"17","author":"Prins","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.prp.2025.156326_bib232","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00262-016-1905-7","article-title":"Phase I\/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma","volume":"65","author":"Akasaki","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.prp.2025.156326_bib233","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S2352-4642(23)00031-7","article-title":"Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial","volume":"7","author":"Thompson","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"issue":"14","key":"10.1016\/j.prp.2025.156326_bib234","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1158\/1078-0432.CCR-21-0446","article-title":"Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma","volume":"27","author":"Ellingson","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib235","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/neuonc\/noae105","article-title":"Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy","volume":"26","author":"Noh","year":"2024","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.prp.2025.156326_bib236","doi-asserted-by":"crossref","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2025.156326_bib237","article-title":"Combination of immunotherapy and radiotherapy for recurrent malignant gliomas: results from a prospective study","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"issue":"7903","key":"10.1016\/j.prp.2025.156326_bib238","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib239","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s002590050397","article-title":"Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin","volume":"26","author":"Paganelli","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib240","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.115.154401","article-title":"TGF-\u03b2 antibody uptake in recurrent high-grade glioma imaged with 89Zr-Fresolimumab PET","volume":"56","author":"den Hollander","year":"2015","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.prp.2025.156326_bib241","first-page":"912","article-title":"Novel human IgG2b\/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results","volume":"47","author":"Reardon","year":"2006","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.prp.2025.156326_bib242","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00280-019-03879-2","article-title":"Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII","volume":"84","author":"Rosenthal","year":"2019","journal-title":"Cancer Chemother. Pharm."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib243","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.prp.2025.156326_bib244","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/neuonc\/noy202","article-title":"Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma","volume":"21","author":"Kieran","year":"2019","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.prp.2025.156326_bib245","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1078-0432.CCR-21-2347","article-title":"NOTCH-induced MDSC recruitment after oHSV Virotherapy in CNS cancer models modulates antitumor immunotherapy","volume":"28","author":"Otani","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.prp.2025.156326_bib246","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro Oncol."},{"issue":"10","key":"10.1016\/j.prp.2025.156326_bib247","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1158\/1078-0432.CCR-07-4875","article-title":"Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme","volume":"14","author":"De Vleeschouwer","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.prp.2025.156326_bib248","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2025.156326_bib249","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11060-017-2413-0","article-title":"Immunotherapy and radiation in glioblastoma","volume":"134","author":"Sahebjam","year":"2017","journal-title":"J. Neuro Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825005199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825005199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:37:46Z","timestamp":1767973066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825005199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":249,"alternative-id":["S0344033825005199"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.156326","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing glioblastoma immunotherapy: Molecular pathways and innovative therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.156326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156326"}}